Rhumbline Advisers Cellectis S.A. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Cellectis S.A. stock. As of the latest transaction made, Rhumbline Advisers holds 3,855 shares of CLLS stock, worth $7,902. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,855
Previous 3,855
-0.0%
Holding current value
$7,902
Previous $11,000
9.09%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CLLS
# of Institutions
31Shares Held
9.83MCall Options Held
0Put Options Held
30.9K-
Long Focus Capital Management, LLC San Juan, PR4.49MShares$9.2 Million0.64% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$3.79 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.95 Million0.0% of portfolio
-
Baillie Gifford & CO827KShares$1.7 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA425KShares$870,2920.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $93.3M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...